menu search

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am

Abbvie's upadacitinib (rinvoq®) met primary and most ranked secondary endpoints in phase 3 study for non-radiographic axial spondyloarthritis

NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AX...

October 7, 2021, 8:16 am


Search within

Pages Search Results: